ArticleIJTLD open2024
Savings from the introduction of BPaL and BPaLM regimens at the country level.
Article in IJTLD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024.China CDC weekly · 2026Article
- Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis.BMJ global health · 2026Article
- Effectiveness and safety of the BPaL regimen in the Philippines.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines.IJTLD open · 2025Article
- Pakistan's path forward in DR-TB management: insights from global implementation of BPaL/BPaLM regimen.Annals of medicine and surgery (2012) · 2025Article
- Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India.International journal of technology assessment in health care · 2025Article
- Analysis of the impact of crises tuberculosis incidence in Ukraine amid pandemics and war.Scientific reports · 2025Article
- Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy.IJTLD open · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB. SLASH-TB estimates the cost-saving and cost-effectiveness for the healthcare system and patients when a country switches from current standard-of-care treatment regimens to BPaL/BPaLM. METHODOLOGY: Country data from national TB programmes (NTP) are used to calculate the costs for all regimens and treatment outcomes. Where BPaL/BPaLM is not currently used, clinical trial outcomes data are used to estimate cost-effectiveness. DALYs are calculated using the Global Burden of Disease (GBD) database.
resultsWe present the results of four countries that have used the tool and shared their data. When shorter and longer regimens are replaced with BPaL/BPaLM, the savings per patient treated in Pakistan, the Philippines, South Africa, and Ukraine are $746, $478, $757, and $2,636, respectively. An increased number of patients would be successfully treated with BPaL/BPaLM regimens, with 411, 1,025, 1,371 and 829 lives saved and 20,179, 27,443, 33,384 and 21,924 DALYs averted annually in the four countries, respectively.
conclusionThrough BPaL/BPaLM regimens, drug-resistant TB treatment has become more effective, shorter, less burdensome for patients, cheaper for both health systems and patients, and saves more lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.